PL EN
REVIEW PAPER
 
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
COVID-19 disease, caused by the SARS-CoV-2 virus, has been recognised as a pandemic by WHO since 11 March 2020. It has been estimated that the disease is responsible for the death of 3.11 million people worldwide. Although several therapeutic agents have been evaluated for the treatment of COVID-19 disease, vaccines are considered to be the safest form of protecting patients against COVID-19.

Objective:
The aim of this review was to present the literature data and the latest recommendations on risks related with COVID-19 vaccines.The latest literature was reviewed based on PubMed and Google Scholar databases, using the following keywords: COVID-19; vaccines; safety

Abbreviated description of the state of knowledge:
The safety of each vaccine is vital for controllling the pandemic. Due to the fact that vaccines have been launched quite recently and their production technologies are different, the safety of each preparation should be looked into separately. Nucleic acids do not trigger such a strong immune response on their own as viral vectors, chich is why mRNA vaccines seem to be the safest types of vaccines. In December 2020, a year after detection of the first case of by SARS-CoV-2 infection in humans, the first anti-COVID-19 vaccine became available.

Conclusions:
Anti-COVID-19 vaccines do not seem to cause many adverse events and side-effects, such as fever, chills, muscle pain, headache and fatigue. These are not serious and subside after taking over-the-counter pain relievers. Currently, there is no information on the safety and efficacy of vaccines in pregnant and breast-feeding women; international expert recommendations leave the decision about vaccination with the woman, who should previously consult with her doctor about the benefits and risks involved

 
REFERENCES (31)
1.
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 – Final Report. N Engl J Med. 2020; 383(19): 1813–1826. doi: 10.1056/NEJMoa2007764.
 
2.
WHO Solidarity Trial Consortium; Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. N Engl J Med 2021; 384(6): 497–511. doi: 10.1056/NEJMoa2023184.
 
3.
Smieszek SP, Przychodzen BP, Polymeropoulos MH. Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment. Int J Antimicrob Agents. 2020; 55(6): 106004. doi: 10.1016/j.ijantimicag.2020.106004.
 
4.
Kandimalla R, John A, Abburi C, et al. Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics. Mol Neurobiol. 2020; 57(10): 4106–4116. doi: 10.1007/s12035-020-02022-0.
 
5.
Sharma O, Sultan AA, Ding H, et al. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol. 2020; 11: 585354. doi: 10.3389/fimmu.2020.585354.
 
6.
EMA recommends first COVID-19 vaccine for authorisation in the EU. https://www.ema.europa.eu/en/n... ema-recommends-first-covid-19-vaccine-authorisation-eu (access: 18.02.2021).
 
7.
ht t ps://szczepienia.pzh.gov.pl/wsz yst ko-o-szczepieniach/lista-dostepnych-szczepionek/ state of the knowledge on 01.05.2021.
 
8.
Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020; 288: 198114. doi: 10.1016/j.virusres.2020.198114.
 
9.
Pascolo S. Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype. Viruses. 2021; 13(2): 270. doi: 10.3390/v13020270.
 
10.
Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing. 2021; 50(2): 279–283. doi: 10.1093/ageing/afaa274.
 
11.
Gee J, Marquez P, Su J, et al. First Month of COVID-19 Vaccine Safety Monitoring – United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(8): 283–288. doi: 10.15585/mmwr.mm7008e3.
 
12.
Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27): 2603–2615. doi: 10.1056/NEJMoa2034577.
 
13.
Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020; 383(25): 2439–2450. doi: 10.1056/NEJMoa2027906.
 
14.
Monin-Aldama L, Laing AG, et al. Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines. medRxiv, 3 2021. doi: https://doi.org/10.1101/2021.0....
 
15.
Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021; 397(10280): 1178–1181. doi: 10.1016/S0140-6736(21)00502-X.
 
16.
Cirillo N. Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns. J Oral Pathol Med. 2021; 50(4): 424–427. doi: 10.1111/jop.13165.
 
17.
Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol. 2013; 11(12): 836–48. doi: 10.1038/nrmicro3143.
 
18.
Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249): 467–478. doi: 10.1016/S0140-6736(20)31604-4.
 
19.
Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immuno-genicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021; 396(10267): 1979–1993. doi: 10.1016/S0140-6736(20)32466-1.
 
20.
https://w w w.ema.europa.eu/en/events/pres... state of the knowledge on 01.05.2021.
 
21.
Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021. doi: 10.1056/NEJMoa2104882.
 
22.
Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J.Med. 2021: NEJMoa2104840. doi: 10.1056/NEJMoa2104840.
 
23.
https://wintoncentre.maths.cam... state of the knowledge on 01.05.2021.
 
24.
Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021. doi: 10.1056/NEJMoa2101544.
 
25.
Sonja A. Rasmussen, Colleen F. Kelley, et al. Coronavirus Disease 2019 (COVID-19) Vaccines and Pregnancy: WhatObstetricians Need to Know. Obstetrics and Gynecology, 137, 3, 3 2021. doi: 10.1097/AOG.0000000000004290.
 
26.
Male V. Are COVID-19 vaccines safe in pregnancy? Nat Rev Immunol. 2021; 21(4): 200–201. doi: 10.1038/s41577-021-00525-y.
 
27.
https://www.gov.pl/web/szczepi... state of the knowledge on 01.05.2021.
 
28.
Perl SH, Uzan-Yulzari A, Klainer H, et al. SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women. JAMA, 2021; e215782. doi: 10.1001/jama.2021.5782.
 
29.
Fouda GGA, Kwiek JJ, Yotebieng M. Safety of Breastfeeding by Mothers With COVID-19: New Evidence From Israel. Pediatrics. 2021; 147(5): e2020049772. doi: https://doi.org/10.1542/peds.2....
 
30.
Mayo S, Monfort S. Letter to the Editor: Breastfeeding and COVID-19 Vaccine: Yes We Can. J Hum Lact. 2021; 37(2): 275–276. doi: 10.1177/08903344211004443.
 
31.
Gray KJ, Bordt EA, Atyeo C, et al. COVID-19 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021: S0002-9378(21)00187-3. doi: 10.1016/j.ajog.2021.03.023.
 
eISSN:2084-4905
ISSN:2083-4543